The Prostate Cancer Foundation (PCF) will convene leading researchers, clinicians and industry experts at its 33rd Annual Scientific Retreat, October 2–4, 2026, in Carlsbad, California. The Retreat is ...

For more than a decade, patients facing certain types of prostate cancer have been able to turn to Xtandi, the now-brand name of enzalutamide, a compound breakthrough developed in the lab of Michael ...

The Georgetown University Lombardi Comprehensive Cancer Center held a lecture on how certain white blood cells in the immune system can contribute to bone metastatic prostate cancer as part of their ...

Three phase 3 prostate cancer results from ESMO 2026 cover long-term survival with abiraterone in metastatic disease, Erleada before and after surgery, and an update on Truqap for PTEN-deficient ...